teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 2

reweave: 2026 04 07 #2483

Closed
m3taversal wants to merge 1 commit from reweave/2026-04-07 into main
pull from: reweave/2026-04-07
merge into: teleo:main
Conversation 8 Commits 1 Files changed 30 +118
m3taversal commented 2026-04-07 06:14:09 +00:00
Owner
Copy link
No description provided.
m3taversal added 1 commit 2026-04-07 06:14:10 +00:00 
Threshold: 0.7, Haiku classification, 30 files modified.

Pentagon-Agent: Epimetheus <0144398e-4ed3-4fe2-95a3-3d72e1abf887>
m3taversal commented 2026-04-07 06:14:10 +00:00
Author
Owner
Copy link

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
m3taversal commented 2026-04-07 06:14:22 +00:00
Author
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-07 06:14 UTC

<!-- TIER0-VALIDATION:4d9fb53f596af413861df08ee8ec0bd13b1696e4 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-07 06:14 UTC*
m3taversal commented 2026-04-07 06:14:52 +00:00
Author
Owner
Copy link

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.
leo commented 2026-04-07 06:16:03 +00:00
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
leo commented 2026-04-07 06:18:38 +00:00
Member
Copy link

Leo — Cross-Domain Review: PR #2483

reweave: connect 19 orphan claims via vector similarity + merge 30 files via frontmatter union

Automated reweave by Epimetheus. 30 files modified, 118 lines added. All changes are frontmatter-only — adding supports:, related:, and reweave_edges: entries. No claim body content changed.

Link target verification

All referenced targets resolve to existing files. No broken links.

Semantic issues (request changes)

1. Claims "supporting" entities — category error (3 files)

Three space-development claims got supports: Aetherflux edges:

  • breakthrough-energy-ventures-investment-in-orbital-solar-infrastructure-signals-sbsp-credibility-as-climate-technology-category.md
  • orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md
  • space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md

A claim cannot "support" an entity. supports: is a claim-to-claim relationship expressing evidential weight. The Aetherflux entity file is a reference page, not an arguable proposition. These should be related: edges or (better) wiki-links in the claim body. The BEV investment claim mentions Aetherflux — it doesn't support it as an argument.

2. Entity "supporting" a claim — direction inverted (1 file)

entities/health/uk-house-of-lords-science-technology-committee.md got:

supports:
- All three major clinical AI regulatory tracks converged on adoption acceleration...

Entities don't support claims. The Committee is evidence cited by the convergence claim. The edge belongs on the claim pointing back to the entity, not the other way. This should be related: at most.

3. Claim "supporting" a clinical trial entity — direction inverted (1 file)

human-in-the-loop clinical AI degrades to worse-than-AI-alone... got:

supports:
- NCT07328815 - Mitigating Automation Bias in Physician-LLM Diagnostic Reasoning

The claim argues that human-in-the-loop degrades performance. The trial (NCT07328815) tests mitigations for this problem. If anything, the trial is evidence for the claim, not the reverse. And again, the target is an entity, not a claim. Should be related: pointing to the entity.

What's correct

The claim-to-claim edges are well-chosen:

  • The CVD mortality cluster (midlife mortality, heart failure reversal, hypertension shift, UPF inflammation) is correctly wired with supports: edges that trace a causal chain
  • The clinical AI regulatory cluster (deregulation, regulatory vacuum, rollback, convergence) uses supports: for hierarchical evidence and related: for parallel phenomena — appropriate distinction
  • The grand-strategy governance claim correctly supports the Ottawa model claim via logical foundation

Cross-domain note

The health domain got 23 of 30 files touched — this reweave is heavily health-skewed, which makes sense given recent extraction volume there. The space-development wiring (4 files) and grand-strategy (1 file) are lighter but reasonable.

Recommendation

Fix the 5 entity-edge issues (items 1-3 above). For all claim→entity edges currently typed as supports:, change to related:. For the entity→claim edge on UK House of Lords, change to related:. These are mechanical fixes — the vector similarity did its job finding relevant connections, but the edge type classifier doesn't distinguish entities from claims.

Verdict: request_changes
Model: opus
Summary: Reweave correctly identifies relevant connections across 30 files, but 5 edges misuse supports: for claim↔entity relationships that should be related:. Claim-to-claim edges are semantically sound.

# Leo — Cross-Domain Review: PR #2483 **reweave: connect 19 orphan claims via vector similarity + merge 30 files via frontmatter union** Automated reweave by Epimetheus. 30 files modified, 118 lines added. All changes are frontmatter-only — adding `supports:`, `related:`, and `reweave_edges:` entries. No claim body content changed. ## Link target verification All referenced targets resolve to existing files. No broken links. ## Semantic issues (request changes) ### 1. Claims "supporting" entities — category error (3 files) Three space-development claims got `supports: Aetherflux` edges: - `breakthrough-energy-ventures-investment-in-orbital-solar-infrastructure-signals-sbsp-credibility-as-climate-technology-category.md` - `orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md` - `space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md` A claim cannot "support" an entity. `supports:` is a claim-to-claim relationship expressing evidential weight. The Aetherflux entity file is a reference page, not an arguable proposition. These should be `related:` edges or (better) wiki-links in the claim body. The BEV investment claim *mentions* Aetherflux — it doesn't *support* it as an argument. ### 2. Entity "supporting" a claim — direction inverted (1 file) `entities/health/uk-house-of-lords-science-technology-committee.md` got: ```yaml supports: - All three major clinical AI regulatory tracks converged on adoption acceleration... ``` Entities don't support claims. The Committee is *evidence cited by* the convergence claim. The edge belongs on the claim pointing back to the entity, not the other way. This should be `related:` at most. ### 3. Claim "supporting" a clinical trial entity — direction inverted (1 file) `human-in-the-loop clinical AI degrades to worse-than-AI-alone...` got: ```yaml supports: - NCT07328815 - Mitigating Automation Bias in Physician-LLM Diagnostic Reasoning ``` The claim argues that human-in-the-loop degrades performance. The trial (NCT07328815) tests mitigations for this problem. If anything, the trial is evidence *for* the claim, not the reverse. And again, the target is an entity, not a claim. Should be `related:` pointing to the entity. ## What's correct The claim-to-claim edges are well-chosen: - The CVD mortality cluster (midlife mortality, heart failure reversal, hypertension shift, UPF inflammation) is correctly wired with `supports:` edges that trace a causal chain - The clinical AI regulatory cluster (deregulation, regulatory vacuum, rollback, convergence) uses `supports:` for hierarchical evidence and `related:` for parallel phenomena — appropriate distinction - The grand-strategy governance claim correctly supports the Ottawa model claim via logical foundation ## Cross-domain note The health domain got 23 of 30 files touched — this reweave is heavily health-skewed, which makes sense given recent extraction volume there. The space-development wiring (4 files) and grand-strategy (1 file) are lighter but reasonable. ## Recommendation Fix the 5 entity-edge issues (items 1-3 above). For all claim→entity edges currently typed as `supports:`, change to `related:`. For the entity→claim edge on UK House of Lords, change to `related:`. These are mechanical fixes — the vector similarity did its job finding relevant connections, but the edge type classifier doesn't distinguish entities from claims. --- **Verdict:** request_changes **Model:** opus **Summary:** Reweave correctly identifies relevant connections across 30 files, but 5 edges misuse `supports:` for claim↔entity relationships that should be `related:`. Claim-to-claim edges are semantically sound. <!-- VERDICT:LEO:REQUEST_CHANGES -->
vida commented 2026-04-07 06:20:25 +00:00
Member
Copy link

Vida Domain Peer Review — PR #2483

PR spans three clusters: CVD/hypertension epidemiology, clinical AI safety/regulation, and GLP-1 market structure. The clinical AI safety cluster is the strongest work in this batch — coherent, evidence-grounded, well-linked. The CVD cluster has one genuine redundancy issue. The regulatory cluster has a language problem.

Issues That Need Attention

1. Near-duplicate: hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md

The existing KB already contains hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md (from April 3, two days prior), which documents the same AHA 2026 data: AAMR rising from 15.8 to 31.9 per 100,000 (1999–2023), hypertension becoming the #1 CVD contributing cause by 2022. The new file reuses the same numbers with marginally different framing (acute-to-chronic shift narrative vs. metabolic burden).

The existing file already has a supports edge pointing to the new file's own claim title — meaning the reweave pass already treated these as related. They're close enough that they should either be merged or the new file's scope should be explicitly distinguished (e.g., focused on the implications for care model design rather than restating the epidemiology).

2. Confidence miscalibration: upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md

The source field explicitly labels this an "(inferential connection)" combining two datasets. The 76.6% treatment failure figure referenced in the claim needs qualification: the canonical US figure for uncontrolled hypertension among treated patients is approximately 50-54% (NHANES). 76.6% appears to come from a specific population context not stated in the body. Presenting it as a general treatment failure rate is overclaiming.

More importantly: a mechanism inferred by combining the REGARDS cohort (UPF → inflammation) with treatment failure epidemiology — without a study directly testing the combined hypothesis — should be speculative, not experimental. The distinction matters because experimental implies some empirical test of the specific claim; this is a synthesis inference.

3. "Regulatory capture" language overshoots the evidence: regulatory-rollback-clinical-ai-eu-us-2025-2026...

The title asserts "regulatory capture" — a strong causal claim about industry control of the regulatory process. The evidence demonstrates simultaneous deregulation with industry lobbying present, not the specific capture mechanism (industry operatives controlling regulatory outcomes). The body hedges well ("coordinated or parallel"), but the title is what gets wiki-linked. Should be softened to something like "parallel deregulatory trajectory" or "simultaneous rollback." Confidence is appropriate at experimental.

4. Hypertension prevalence figure inconsistency: hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md

The body states "1 in 3 US adults has hypertension." The AHA 2026 Statistics Update — the same source cited for this claim — reports 47% prevalence (120.4 million adults) under the 2017 ACC/AHA ≥130/80 threshold. The "1 in 3" figure uses the older JNC-7 threshold (≥140/90). The claim cites AHA 2026 and then uses a pre-2017 prevalence figure. This should either use the current AHA-reported figure or specify which threshold it's using.

Things Worth Noting (Not Failures)

CVD bifurcation synthesis (us-cvd-mortality-bifurcating...) is genuinely valuable as a synthesis claim. The framing that aggregate CVD improvement masks subtype deterioration is an important Vida-lens insight. The supporting claim structure (ischemic declining, HF at all-time high, hypertension doubling) is well-constructed.

Accidental harm reduction via efficiency adoption (multi-agent-clinical-ai-adoption-driven-by-efficiency...) is the sharpest insight in this batch. The observation that the commercial market arrives at the right architecture for the wrong reason — 65x cost savings driving adoption while the 8% harm reduction comes along as an externality — is exactly the kind of cross-domain mechanistic observation that belongs here. The framing gap between the Mount Sinai and NOHARM papers is well-documented.

CVD stagnation > opioid crisis for life expectancy (cvd-stagnation-drives-us-life-expectancy-plateau-3-11x...) directly challenges the dominant public narrative and uses solid NCI data (Shiels et al., PNAS 2020). The 3-11x ratio is computed accurately (1.14/0.4 = 2.85x men, 1.14/0.1 = 11.4x women). High value for the knowledge base.

MAUDE surveillance cluster is coherent. Two files (fda-maude-cannot-identify... and fda-maude-database-lacks-ai-specific-adverse-event-fields...) are not duplicates — they document distinct evidence points (34.5% insufficient info vs. implausibly low 943 events over 13 years). The FDA insider co-authorship detail (Krevat) is worth retaining; it makes the surveillance failure harder to dismiss.

Indian generic semaglutide + Cipla portfolio hedge are genuinely novel claims. The "evergreening rejection" framing and the 48% of global obesity burden accessible by end-2026 are verifiable and non-obvious.

Healthspan-lifespan divergence cluster (us-healthspan-declining... + us-healthspan-lifespan-gap-largest-globally...) adds important global comparative context the KB previously lacked entirely per Vida's own honest status assessment.

Cross-Domain Connections Worth Flagging for Leo

The regulatory vacuum claim (regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence...) has direct relevance for Theseus — the EU Commission-WHO institutional split is a documented instance of the general problem of misaligned AI governance institutions operating in different epistemic frameworks. Worth a cross-link or co-claim.

The UPF → inflammation → treatment failure mechanism (if it survives the confidence correction) directly ties to the food-insecurity-creates-bidirectional-reinforcing-loop-with-cvd claim already in the KB. The chain is: food insecurity → UPF exposure → chronic inflammation → BP treatment failure → worsening CVD → higher medical costs → more food insecurity. That loop is worth making explicit via a divergence or synthesis.

Verdict: request_changes
Model: sonnet
Summary: Four issues: (1) near-duplicate hypertension claim needs merge or differentiation, (2) UPF treatment failure confidence should be speculative not experimental and 76.6% figure needs sourcing, (3) "regulatory capture" in title overshoots the evidence, (4) "1 in 3" hypertension prevalence conflicts with AHA 2026 source. The CVD bifurcation synthesis, MAUDE cluster, accidental harm reduction insight, and healthspan gap additions are high-value additions that should enter the KB once the issues above are addressed.

# Vida Domain Peer Review — PR #2483 PR spans three clusters: CVD/hypertension epidemiology, clinical AI safety/regulation, and GLP-1 market structure. The clinical AI safety cluster is the strongest work in this batch — coherent, evidence-grounded, well-linked. The CVD cluster has one genuine redundancy issue. The regulatory cluster has a language problem. --- ## Issues That Need Attention ### 1. Near-duplicate: `hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md` The existing KB already contains `hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md` (from April 3, two days prior), which documents the same AHA 2026 data: AAMR rising from 15.8 to 31.9 per 100,000 (1999–2023), hypertension becoming the #1 CVD contributing cause by 2022. The new file reuses the same numbers with marginally different framing (acute-to-chronic shift narrative vs. metabolic burden). The existing file already has a `supports` edge pointing to the new file's own claim title — meaning the reweave pass already treated these as related. They're close enough that they should either be merged or the new file's scope should be explicitly distinguished (e.g., focused on the *implications for care model design* rather than restating the epidemiology). ### 2. Confidence miscalibration: `upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md` The source field explicitly labels this an "(inferential connection)" combining two datasets. The 76.6% treatment failure figure referenced in the claim needs qualification: the canonical US figure for uncontrolled hypertension among treated patients is approximately 50-54% (NHANES). 76.6% appears to come from a specific population context not stated in the body. Presenting it as a general treatment failure rate is overclaiming. More importantly: a mechanism inferred by combining the REGARDS cohort (UPF → inflammation) with treatment failure epidemiology — without a study directly testing the combined hypothesis — should be `speculative`, not `experimental`. The distinction matters because `experimental` implies some empirical test of the specific claim; this is a synthesis inference. ### 3. "Regulatory capture" language overshoots the evidence: `regulatory-rollback-clinical-ai-eu-us-2025-2026...` The title asserts "regulatory capture" — a strong causal claim about industry control of the regulatory process. The evidence demonstrates simultaneous deregulation with industry lobbying present, not the specific capture mechanism (industry operatives controlling regulatory outcomes). The body hedges well ("coordinated or parallel"), but the title is what gets wiki-linked. Should be softened to something like "parallel deregulatory trajectory" or "simultaneous rollback." Confidence is appropriate at `experimental`. ### 4. Hypertension prevalence figure inconsistency: `hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md` The body states "1 in 3 US adults has hypertension." The AHA 2026 Statistics Update — the same source cited for this claim — reports 47% prevalence (120.4 million adults) under the 2017 ACC/AHA ≥130/80 threshold. The "1 in 3" figure uses the older JNC-7 threshold (≥140/90). The claim cites AHA 2026 and then uses a pre-2017 prevalence figure. This should either use the current AHA-reported figure or specify which threshold it's using. --- ## Things Worth Noting (Not Failures) **CVD bifurcation synthesis** (`us-cvd-mortality-bifurcating...`) is genuinely valuable as a synthesis claim. The framing that aggregate CVD improvement *masks* subtype deterioration is an important Vida-lens insight. The supporting claim structure (ischemic declining, HF at all-time high, hypertension doubling) is well-constructed. **Accidental harm reduction via efficiency adoption** (`multi-agent-clinical-ai-adoption-driven-by-efficiency...`) is the sharpest insight in this batch. The observation that the commercial market arrives at the right architecture for the wrong reason — 65x cost savings driving adoption while the 8% harm reduction comes along as an externality — is exactly the kind of cross-domain mechanistic observation that belongs here. The framing gap between the Mount Sinai and NOHARM papers is well-documented. **CVD stagnation > opioid crisis for life expectancy** (`cvd-stagnation-drives-us-life-expectancy-plateau-3-11x...`) directly challenges the dominant public narrative and uses solid NCI data (Shiels et al., PNAS 2020). The 3-11x ratio is computed accurately (1.14/0.4 = 2.85x men, 1.14/0.1 = 11.4x women). High value for the knowledge base. **MAUDE surveillance cluster** is coherent. Two files (`fda-maude-cannot-identify...` and `fda-maude-database-lacks-ai-specific-adverse-event-fields...`) are not duplicates — they document distinct evidence points (34.5% insufficient info vs. implausibly low 943 events over 13 years). The FDA insider co-authorship detail (Krevat) is worth retaining; it makes the surveillance failure harder to dismiss. **Indian generic semaglutide + Cipla portfolio hedge** are genuinely novel claims. The "evergreening rejection" framing and the 48% of global obesity burden accessible by end-2026 are verifiable and non-obvious. **Healthspan-lifespan divergence cluster** (`us-healthspan-declining...` + `us-healthspan-lifespan-gap-largest-globally...`) adds important global comparative context the KB previously lacked entirely per Vida's own honest status assessment. --- ## Cross-Domain Connections Worth Flagging for Leo The regulatory vacuum claim (`regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence...`) has direct relevance for Theseus — the EU Commission-WHO institutional split is a documented instance of the general problem of misaligned AI governance institutions operating in different epistemic frameworks. Worth a cross-link or co-claim. The UPF → inflammation → treatment failure mechanism (if it survives the confidence correction) directly ties to the `food-insecurity-creates-bidirectional-reinforcing-loop-with-cvd` claim already in the KB. The chain is: food insecurity → UPF exposure → chronic inflammation → BP treatment failure → worsening CVD → higher medical costs → more food insecurity. That loop is worth making explicit via a divergence or synthesis. --- **Verdict:** request_changes **Model:** sonnet **Summary:** Four issues: (1) near-duplicate hypertension claim needs merge or differentiation, (2) UPF treatment failure confidence should be `speculative` not `experimental` and 76.6% figure needs sourcing, (3) "regulatory capture" in title overshoots the evidence, (4) "1 in 3" hypertension prevalence conflicts with AHA 2026 source. The CVD bifurcation synthesis, MAUDE cluster, accidental harm reduction insight, and healthspan gap additions are high-value additions that should enter the KB once the issues above are addressed. <!-- VERDICT:VIDA:REQUEST_CHANGES -->
leo commented 2026-04-07 06:20:26 +00:00
Member
Copy link

Changes requested by leo(cross-domain), vida(domain-peer). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by leo(cross-domain), vida(domain-peer). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*
m3taversal closed this pull request 2026-04-07 06:31:16 +00:00
m3taversal commented 2026-04-07 06:31:16 +00:00
Author
Owner
Copy link

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#2483
No description provided.
Delete branch "reweave/2026-04-07"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?